Predictive Oncology (NASDAQ: POAI) is taking a unique approach to cancer treatment by utilizing its proprietary database of cancer cases using the proven power of artificial intelligence (“AI”). A recent article discussing the company reads, “The company works alongside pharmaceutical, diagnostic and biotechnology industry players to develop highly customizable assessment methods that can be applied to both individualize current therapies and develop the next generation of precision therapies, leading to better outcomes for patients. The company recently announced a corporate name change from Precision Therapeutics to Predictive Oncology Inc., which reflects its mission and strategic emphasis. . . . Predictive Oncology seeks to revolutionize the way cancer is treated for both the patients of today and those of tomorrow. The company is well positioned to do exactly that as a result of two key assets: its ability to grow patients’ own tumors in the laboratory and test the tumors’ responses to chemotherapy, together with its existing database of outcome data cataloguing more than 150,000 tumors and their specific responses to those chemotherapies.”
Predictive Oncology (formerly Precision Therapeutics Inc.) operates through its three business units: Helomics, TumorGenesis and Skyline Medical. Helomics applies artificial intelligence to rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient-treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision-oncology platform, Helomics offers boutique CRO services that leverage its TruTumor, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Food safety companies have for long used radio frequency technology to disinfect food. Now this technology is being adopted by the marijuana industry in order to kill pathogens like mold and mildew while maintaining the quality of the marijuana.
The existing methods that were the staple in the industry all came with their own challenges, and this new technique addresses all those…
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
NEW YORK, Sept. 19, 2019 — via NetworkNewsAudio – SRAX Inc. (NASDAQ: SRAX) today announces the broadcast of its exclusive audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community.
SRAX CEO and Founder Christopher Miglino joins NNW’s Stuart Smith for a review of the company’s impressive growth pattern during the past year and its goals for the future.
SRAX is a digital marketing and consumer data management technology company. Its technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. The company’s consumer data management and distribution system, BIGtoken, continues to grow and currently has 16 million users.
“Our goal is to build the most valuable opted-in data set in the world. We’ll have more consumers that have opted in to let us sell access to their data than any other company and that’s invaluable,” says Miglino.
SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury, and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.
Miglino said consumers are beginning to realize their data has true value and are taking back their data. Privacy concerns are rippling throughout Europe and the U.S., with several countries and states passing laws that regulate or control the amount of opt in and opt out a website publisher – such as Facebook – can impose on users.
SRAX provides a solution to privacy issues through BIGtoken, which allows users to opt in and let companies access their data in exchange for compensation. SRAX has partnered with several high-profile nonprofit associations to provide BIGtoken users the ability to donate their earnings. Several well-known consumer packed good brands have signed up to utilize BIGtoken to reward users for access to data as well.
The company’s SRAX Investor Relations program, currently licensed for $3,000 a month to about 20 publicly traded companies, provides data about the company’s investors and shareholders, and provides tools to manage those relationships across a wide spectrum of platforms. SRAX is working toward reaching a goal of 100 publicly traded company partners by the end of 2019.
SRAX Inc. (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through the BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data thereby providing everyone in the Internet ecosystem choice, transparency, and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury, and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information on SRAX, visit www.srax.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/Rf8do
About NetworkNewsAudio
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
POAI’s artificial intelligence (AI)-driven tumor profiling platform brings precision medicine tools to clinicians and researchers to improve cancer outcomes
The company holds a critical strategic advantage over mammoth competitors, attracting investor attention
POAI is committed to providing sophisticated tools to help select current therapies more precisely and develop new targeted therapies
Predictive Oncology Inc. (NASDAQ: POAI) is working with the pharmaceutical and biotech industries to offer an AI-driven tumor profiling platform that clinicians and researchers can use to improve outcomes for cancer patients of today and tomorrow. POAI has built a distinctly valuable asset in its existing base of drug-response outcome evidence; this data has the potential to revolutionize the way cancer is treated (http://nnw.fm/3mDNw).
Though seeming like David in the face of Goliath-sized competition, POAI holds a critical strategic advantage over such mammoth companies as Foundation Medicine and Tempus; while these competitors must wait at least five years to find out if the patient survived treatment before they can show value from their…
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Opportunity to witness the cutting-edge engineering and technology that went into building TGOD’s facilities and see how the Company quickly scales organic production to be the global certified organic leader
Taking participants behind the scenes of what will be the world’s largest organic cannabis cultivation facility (Valleyfield site) as the first phase nears completion
Product portfolio finalized in time for legalization 2.0; participants will have the opportunity to sample non-infused beverage formulations
TORONTO, Sept. 19, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF), a leading producer of premium certified organic cannabis, is pleased to announce that it is hosting site visits for analysts at its Hamilton and Valleyfield facilities on September 19-20. Beyond construction timelines, for the first time the Company is sharing Canadian production ramp-up and other updates which are available on TGOD’s website at www.tgod.ca.
“We are doing something no other producer has done before, growing premium certified organic cannabis at scale. By leveraging our proprietary growing methods, purpose-built facilities and industry-leading horticultural team, we are creating a wide economic moat within the premium organic segment,” commented Brian Athaide, CEO of TGOD. “We are extremely proud to showcase the hard work that went into designing and building these state-of-the-art facilities as well as our cannabis 2.0 portfolio.”
Highlights
Approximately 25 analysts from Canada and the United States participating.
Growing team will showcase TGOD’s grow differentiation and proprietary horticultural practices.
Tour includes walk through of TGOD’s purpose-built facilities designed specifically for certified organic cannabis cultivation.
Hamilton hybrid greenhouse now completed; all rooms licensed by Health Canada, bringing total annual production capacity for the site to 17,500 kg.
Valleyfield first phase on track to be completed in Q4 with the first harvest in early 2020, taking annual production capacity for the site to 65,000 kg.
Cannabis 2.0 portfolio unveiling, including non-infused beverage formulations sampling.
Large scale cultivation combined with premium pricing will generate industry-leading margins.
About The Green Organic Dutchman Holdings Ltd. The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US-OTC: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.
TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.
For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.
Forward-Looking Information Cautionary Statement This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about construction and future production, statements about analysts and investors participation level, statement about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “should”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties (including market conditions) and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including those risk factors described in the Company’s most recently filed Annual Information Form available on SEDAR. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
None of the NASDAQ, the TSX nor the TSX’s Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.
Media Relations: Sebastien Bouchard, sbouchard@tgod.ca, (647) 272-2476; Investor Relations: Anthony Davis, adavis@tgod.ca, (905) 304-4201 x 336Copyright CNW Group 2019
Thursday, September 19th, 2019UncategorizedComments Off on $TGODF $TGOD Hosts Analyst Site Visit at Hamilton and Valleyfield Facilities
Predictive Oncology is working to develop highly customizable assessment methods to individualize treatment options for cancer, improving outcomes
POAI’s innovative technology is pioneering in the field of individualizing treatment for ovarian cancer
Predictive Oncology offers potential for significant ROI as it focuses on improving outcomes for cancer patients of today and tomorrow
Predictive Oncology Inc. (NASDAQ: POAI) is harnessing its unique, proprietary database of cancer cases using the proven power of artificial intelligence (AI) to revolutionize treatment outcomes for cancer patients. The company works alongside pharmaceutical, diagnostic and biotechnology industry players to develop highly customizable assessment methods that can be applied to both individualize current therapies and develop the next generation of precision therapies, leading to better outcomes for patients. The company recently announced a corporate name change from Precision Therapeutics to Predictive Oncology Inc., which reflects its mission and strategic emphasis.
Predictive Oncology seeks to revolutionize the way cancer is treated for both the patients of today and those of tomorrow. The company is well positioned to do exactly that as a result of two key assets: its ability to grow patients’ own tumors in the laboratory and test the tumors’ responses to chemotherapy, together with its…
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will present, via webcast, at the Singular Research Midwestern Values Conference on September 19, 2019. Genprex Chairman and CEO Rodney Varner will lead the company’s webcast presentation. The presentation is scheduled to begin at 4:00 PM Central Time, and interested parties may register for the webcast via the Singular Research website.
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Point Roberts, WA and Delta, BC – September 18, 2019 Investorideas.com, a leading investor news resource covering tech and cannabis stocks releases a snapshot reporting on some of the key technology developments impacting the cannabis sector and how companies are deploying “disruptive” technologies to ensure early mover advantage.
Since Federal legalization in Canada, and with new markets opening up every day in either the US or abroad the cannabis industry has become a magnet for game changing technology growth-whether looking at production, extraction, online sales platforms, blockchain technology, packaging and so on, the list is endless.
Looking at the payment sector, Global Payout Inc. (OTC: GOHE), through its wholly owned subsidiary MTrac Tech Corporation, has now reached a point where it is effectively processing tens of millions of dollars in daily transaction volume across its growing base of clients in the multibillion-dollar cannabis industry.
As demonstrated in the Company’s recent Q2 disclosure detailing Company financials, MTrac’s growth trajectory has remained positive and has continued to gain significant traction throughout the year. This growth can be attributed to the successful strengthening of their foothold and market reach in what has become one of the most dynamic industries in today’s economy. This feat has been accomplished in part through MTrac’s success in securing several strategic service agreements with some of the largest companies in the industry today.
This follows on the heels of the launch of MTrac’s massive update to its blockchain powered payment platform, which includes the addition of new banking partners to provide a suite of enhancements to improve the merchant experience through added stability, reliability and system integrity.
Many companies have attempted to solve the cash problem in cannabis and they most certainly have all come to realize the complexities of navigating the financial and regulatory challenges in this constantly evolving industry. The Schedule 1 classification persists as the main deterrent to financial institutions providing its services to cannabis merchants.
“We continue to attract key banking partners with our compliant and seamless solution as an industry leader in this innovative financial technology space,” said Mr. Kevin Curtis, MTrac Chief Strategy Officer. “These strategic updates to the MTrac platform are being done in order to further stabilize the platform and to continue serving our clients in this next growth phase we are embarking upon. The MTrac 3.0 launch is the culmination of key partnerships, significant market share, and our team’s focus on compliance, service, and stability.”
“As these new bank networks are being injected, MTrac is also downsizing the equipment needed to process transactions on the merchant side, which will reduce hardware costs and deployment time to the merchant to enable faster adoption, onboarding, and an improved checkout process for the customer,” said David Flores, EVP. “These updates will also provide unlimited processing bandwidth and more secure transactions with EMV chip and pin debit features, which will allow for overall enhanced merchant and consumer experience.”
The company has recently signed a new account application with an anticipated 34 locations and has applications coming in weekly for the services offered through MTrac.
In addition to their expanding market reach, the Company is also fully engaged with key legislative partners in different states to help push for the adoption of their system as a means of providing merchants within these states with a viable and compliant payment processing alternative to cash as they remain focused on delivering “The Key to Cashless®” to as much of this diverse and expanding industry as possible.
Terra Tech Corp. (OTC: TRTC), has focussed on integrating the best of the natural world with technology to create sustainable solutions for medical cannabis production, extraction and distribution, plant science research and development, food production and Closed Environment Agriculture (CEA).
Through its Blüm Santa Ana dispensary, Terra Tech has been a major supplier of medical and adult-use cannabis to Santa Ana and the surrounding cities, such as Irvine, Laguna Beach and Newport Beach. All of the aforementioned cities suffer from a scarcity of existing cannabis dispensaries. The launch of their premier delivery service has enabled the Company to expand distribution of its best-in-class cannabis products to reach an even greater number of patients and customers.
Terra Tech purchased multiple delivery vans and hired sales associates to deliver products within Orange County, CA, starting with a 20-mile radius out of the Company’s Blüm Santa Ana store.
The company recentlyentered into an agreement to sell 100% of the assets of its Blüm Reno dispensary located at 1085 S Virginia St Suite A, Reno, NV 89502, including the building where the dispensary is located, for a purchase price of $15,000,000.
Terra Tech’s Blüm Reno dispensary has been operational since January 2017 and provides cannabis products to the local medical and adult-use markets, including the Company’s proprietary IVXX brand of premium medical cannabis, flowers, shatters, waxes and oils, among other high-quality cannabis products from a range of reputable providers of superior grade medical cannabis.
Derek Peterson, CEO of Terra Tech, commented, ”Selling the cannabis retail license for our Blüm Reno dispensary is another key milestone in our restructuring plan, a strategy that has been implemented to leverage our balance sheet to fuel growth, as opposed to approaching the capital markets more often than is necessary. Our Blüm dispensary in Reno has substantially increased in value since its opening and selling its assets allows the Company to strategically monetize this asset. To move forward with our restructuring strategy, we plan to redeploy the additional capital generated by this sale toward more productive assets in California in areas such as infrastructure and sales and marketing.”
One company that has been keeping pace with the advanced technology trends coming to the industry is Canopy Rivers Inc. (TSX: RIV.TO) (OTC: CNPOF), a venture capital firm specializing in cannabis. The company recently announced that its portfolio company, TerrAscend Corp. has entered into a distribution agreement with Syqe Medical, Ltd., an Israel-based pharma-tech company, to launch Syqe’s flagship product, The Syqe Inhaler, in Canada.
The Syqe Inhaler is the world’s first metered-dose medical cannabis inhaler and will provide Canadians with an alternative to dried flower medical cannabis. Metered dosing allows patients and healthcare providers to predictably, precisely and consistently deliver treatment at pharmaceutical standards. Syqe’s technology is supported by completed controlled clinical trials, a milestone only a limited number of companies have achieved, with patients suffering from chronic pain. The Syqe treatment provides rapid pain relief while reducing psychoactive effects, allowing patients to resume normal daily activities. The technology was launched in the Israeli market in June 2019.
“We continue to be thrilled with the steps TerrAscend is taking to build an industry-leading business that spans retail, manufacturing, distribution, biotechnology, and now health tech,” said Narbe Alexandrian, President and CEO of Canopy Rivers. “We believe that TerrAscend is uniquely positioned in the Canadian market to deliver on the consumer demand for innovative and rigorously tested products like the Syqe device.”
Canopy Rivers is not only looking at production and consumption technology but also data analytics which is becoming more essential to the industry. One of their investments, Headset, the leading provider of data and analytics to the cannabis industry, recently announced it is launching its competitive intelligence tool, Headset Insights in Canada. Recreational cannabis has been legal country-wide in Canada since October 2018 and the young and growing market is still developing. This will be Canada’s first retail-derived cannabis market read based on aggregated Point of Sale data at the receipt-level.
“This announcement is further proof that Headset will continue to dominate the cannabis data and analytics vertical – first in the United States and now in Canada,” said Mr. Alexandrian. “This announcement validates our belief that in the cannabis industry, like other mature industries, data will be king.”
SinglePoint Inc. (OTCQB: SING) has also been looking at disruptive technology coming to the market with their recent shareholder update on the success of Jacksam/Convectium. As a lead investor in Jacksam before the company went public, SinglePoint was able to secure sizeable interest in the company. Jacksam has now gone public and the value of the company has increased significantly and both parties foresee a very bright future ahead.
“To date, Jacksam has been a tremendous investment for SinglePoint. This is exactly what we look for when investing or acquiring businesses. The company was successful in its original vision and has increased the opportunity for major scalability by opening up the platform. They are now able to work with some of the biggest companies in the space such a CCELL. We are excited to be a part of this high growth company and believe it will only continue its exponential growth,” commented Wil Ralston, President of SinglePoint.
Convectium is the inventor of the world’s first cannabis oil filling system and proprietary packaging systems. This is a major advancement at a time when about 80% of all concentrate products (vapes and pods) are filled manually. By hand, oil cartridge fills are completed at a paltry 75 per hour. Convectium’s 710 Shark system can exceed that in less than a minute on its way to produce between 6,000-12,000 in an hour.
Commenting on their product capabilities, Jacksam/Convectium CEO, Mark Adams stated: “Up until now companies using CCell cartridges couldn’t access our state-of-the-art automation equipment which delivers up to 287% more efficiency and 80% labor savings. Our new ‘open system’ approach catapults our market potential to another level by enabling large-scale CBD or THC concentrate companies to increase output, reduce risks, costs and waste, and beat the competition. These unique machines enable concentrate companies to automate the ‘fill and cap bottleneck’ and cement Convectium’s position as the only true scalable system in the business.”
While production and cultivation remain essential to the growth and stability of the cannabis market, we are starting to see how much of an impact even one of these emerging technologies can have on the ancillary sectors and how some early adopters have been able to achieve massive competitive advantages.
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
Phoenix, Arizona–(September 18, 2019) – The Stock Day Podcast recently welcomed Mr. Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. (OTCQB: PBIO) (“the Company”), to discuss PBIO on Stock Day with its host Mr. Everett Jolley. PBIO is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry.
Mr. Jolly began the interview by welcoming Mr. Schumacher back to the Stock Day Podcast He noted that the Company is continuing to show impressive growth while announcing a number of very impressive achievements.
Mr. Jolly commented: “It’s been about six weeks since you’ve been on the show. During that time there have been several exciting developments at Pressure BioSciences. Please tell us about PBIO and your recent successes.”
Mr. Schumacher explained that the Company has gone through substantial changes over the last 12 months. “A year ago, PBIO had one revenue-generating division. We now have three, each based on our proprietary PCT, BaroFold, or UST platforms.
Mr. Schumacher continued: “Our PCT platform supports our primary business, which is selling pressure-based instruments and consumables to research laboratories worldwide. Our customers include some of the world’s foremost protein chemists, working in many of the finest academic, government, biotech, and phama laboratories around the globe. These scientists use PCT systems for a number of different protein, RNA, and DNA applications as they search to find new biomarkers of disease, diagnostic tools, druggable targets, and therapeutics.”
Mr. Schumacher then expanded on the Company’s late 2017 acquisition of BaroFold, Inc., which secured the development of their second division, their BaroFold BioPharma Services Division. This business unit uses selective and controllable high-pressure to “disaggregate and re-fold” problem proteins intended to be protein-based drugs but because they are aggregated (clumped together) or miss-folded, they can’t be used as a therapeutic. The BaroShear platform can often convert the problem protein back to its correct native structure, which would allow it to be used as a drug. The Company works with manufacturers of protein drugs (of which there are many around the world) to help them correct their aggregated/miss-folded proteins, with the hope that when such proteins have been “fixed”, they could be used as therapeutics to prevent, control, or cure diseases and disabilities. The Company has eight (8) issued patents in this new revenue-generating division.
The Company’s third revenue-generating division is based on their novel and new Ultra Shear Technology (UST) platform. “UST combines ultra-high pressure with intense shearing forces to produce stable, water-soluble nanoemulsions of oil-like products in water. A great example would be the ability to make CBD Oil disperse into water. We have two patents issued in China and believe they will be issued throughout the world in the coming year or two”, explained Mr. Schumacher.
At this point in the interview, Mr. Jolly decided to dive deeper into the various business units of PBI. He noted that the Company’s PCT platform had been recognized recently by prestigious research centers in China and Australia for its pivotal role in the discovery process of cancer biomarkers, as well as for its potential in clinical diagnostics. “Why is that so exciting?” asked Mr. Jolly.
Mr. Schumacher commented: “The system that was highlighted by researchers in two recent journal articles is the PCT system I spoke of just a few minutes ago. It allows scientists to break open cells in an entirely new, safe, and high-quality way”.
Mr. Schumacher added that the PCT System developed by the Company uses high pressure to extract compounds from the cells (like “squeezing a sponge”), including proteins, DNA, RNA, and lipids. Mr. Schumacher noted this this method was very gentle yet powerful as it allows scientists to “dial in” the exact amount of pressure to break the cell (not too much and not too little). He further explained that most methods on the market today use mechanical means to batter the cells in order to extract these important biomolecules in such a way that the mechanical means might damage the biomolecules during the extraction.
Mr. Schumacher also shared that the PCT platform is currently being utilized by these two prestigious facilities in the area of pathology. Currently, biopsy tissues are fixed in formalin and subsequently embedded in paraffin wax (“FFPE”) for long-term storage. It has been estimated that there are more than 1 billion FFPE tissues in laboratories worldwide. The amount of valuable information that could be retrieved from FFPE tissues is enormous. The issue has been developing a method to extract biomolecules – such as proteins – from chemically-fixed and wax embedded FFPE tissues. With the advanced technology provided by the Company’s PCT platform, these two prestigious research facilities have been successful in extracting viable proteins from FFPE tissues, followed by successful analysis of the samples by mass spectrometry.
Mr. Schumacher expanded on this topic: “This means we have a method that scientists can use to extract valuable information on disease detection, progression, control, prevention, and eradication from an almost unlimited supply of biopsy samples.”
Switching topics from the Company’s PCT platform to its new and exciting UST platform, Mr. Jolly noted that the Company recently announced the receipt of two purchase orders for PBI’s revolutionary BaroShear K45 system and asked about the Company’s progress on further potential sales.
Mr. Schumacher explained that the Company currently has patents issued (in China) and filed (worldwide) on this machine. He also noted that PBI has developed a working prototype, which has been used to generate nanoemulsion scale, water-soluble CBD Oil that has been shown to be very soluble in water, juice, energy drinks, and beer. Thus, it has solved one of the biggest issues in the CBD industry today: getting CBD Oil to truly water-soluble, thus allowing it to disperse into water without using large amounts of chemicals.
Mr. Schumacher stated: “We have data that indicates the nano-scale CBD-containing oil droplets that form from processing with UST are stable, water-soluble, and viable – and that no CBD is lost in the manufacturing process. We believe that there is no system on the market today that can compare to our patented BaroShear K45 nanoemulsification system.
Mr. Schumacher then mentioned that based on the enthusiasm generated by their new BaroShear K45 system, and the calls he has received that evidence strong interest in obtaining the machine, he believes that the Company’s revenue in 2020 will be more than double the expected 2019 revenue.
Mr. Jolly then asked Mr. Schumacher for his insight regarding the Company’s market cap and stock price.
Mr. Schumacher commented: “I run the Company like it is a NASDAQ/NYSE company. We have completely independent audit and compensation committees. Our goal is to up-list PBIO to the New York Stock Exchange or the NASDAQ stock exchange in the coming months”, adding that he continually strives to bring value to the Company’s shareholders.
Mr. Jolly closed the interview by sharing that he personally believes the Company is exceptionally undervalued. “For my listeners out there who are looking for different companies to invest in, look no further than Pressure BioSciences”, stated Mr. Jolly.
Pressure BioSciences, Inc. (PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., CBD Oil and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
Please visit us on Facebook, LinkedIn, and Twitter.
Investor Contacts:
Richard T. Schumacher, President and CEO
(508) 230-1828 (T)
Nathan P. Lawrence, Ph.D., Senior Advisor
(508) 230-1829 (F)
About The “Stock Day” Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
SOURCE:
Stock Day Media
602-441-3474
Wednesday, September 18th, 2019UncategorizedComments Off on $PBIO Discusses Major Advancements Its PCT, BaroFold, and BaroShear K45 Platforms
TORONTO, Sept. 17, 2019 – Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, is pleased to announce its portfolio company, TerrAscend Corp. (“TerrAscend“) (CSE: TER) (OTCQX: TRSSF), has entered into a distribution agreement with Syqe Medical, Ltd. (“Syqe“), an Israel-based pharma-tech company, to launch Syqe’s flagship product, the Syqe™ Inhaler, in Canada.
The Syqe Inhaler is the world’s first metered-dose medical cannabis inhaler and will provide Canadians with an alternative to dried flower medical cannabis. Metered dosing allows patients and healthcare providers to predictably, precisely and consistently deliver treatment at pharmaceutical standards. Syqe’s technology is supported by completed controlled clinical trials, a milestone only a limited number of companies have achieved, with patients suffering from chronic pain. The Syqe treatment provides rapid pain relief while reducing psychoactive effects and allowing patients to resume normal daily activities. The technology was launched in the Israeli market in June 2019.
“We continue to be thrilled with the steps TerrAscend is taking to build an industry-leading business that spans retail, manufacturing, distribution, biotechnology, and now health tech,” said Narbe Alexandrian, President and CEO of Canopy Rivers. “We believe that TerrAscend is uniquely positioned in the Canadian market to deliver on the consumer demand for innovative and rigorously tested products like the Syqe device.”
TerrAscend will undertake marketing, distribution, and sales efforts of the Syqe Inhaler through its wholly owned subsidiaries TerrAscend Canada and Solace Health Network. TerrAscend will also provide both guidance on use of the Syqe Inhaler and broader education on the benefits of medical cannabis and the Syqe treatment.
For more information on the agreement between TerrAscend and Syqe, see the joint press release here.
About Canopy Rivers:
Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.
Forward-Looking Statements
This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the benefits of the Syqe technology and its potential as an alternative to dried flower medical cannabis; the Company’s belief that TerrAscend is uniquely positioned in the Canadian market to deliver on the consumer demand for innovative and rigorously tested products; TerrAscend’s plan to market, distribute and sell the Syqe Inhaler through TerrAscend Canada and Solace Health Network and to use its platform to provide guidance on the use of the Syqe Inhaler and broader education on the benefits of medical cannabis and the Syqe treatment; and expectations for other economic, business, and/or competitive factors.
Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; the actual benefits of the Syqe technology and its ability to provide an alterative to dried flower medical cannabis; the ability of TerrAscend and Syqe to collaborate; changes in consumer demand and preferences; changes in TerrAscend’s plans for the Syqe Inhaler and the use of its platform; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ annual information form dated July 15, 2019, filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Tuesday, September 17th, 2019UncategorizedComments Off on $CNPOF $RIV.V Company Licenses Leading Medical Cannabis Vape Technology in Canada
Palm Beach, FL – September 17, 2019 — Global demand for cannabis-based consumer products has been increasing at a rapid pace. In fact, the Brightfield Group estimates the U.S. CBD product market alone to be worth over $23.7 billion by 2023, as CBD finds its way into a variety of consumer product categories including food and beverage, pharmaceuticals, and health and wellness. Analysts at Research and Markets say the global medical cannabis market could be worth up to $44.4 billion by 2024 from just $13.4 billion last year. In addition, analysts at Statista says U.S. medical retail sales could reach $7.3 billion by 2022, as compared to $4.5 billion sales in 2018. Better, according to a May 2018 survey from Nielsen, analysts found that consumers are quickly embracing CBD products, particularly when it comes to medicinal purposes. In fact, according to the survey, 40% of head and migraine suffers are considering cannabis in addition to 40% of all arthritis pain suffers, and 41% of all back and neck pain sufferers. As CBD continues to disrupt major industries, it’s creating a wide range of opportunity for companies such as XPhyto Therapeutics Corp. (CSE:XPHY), HEXO Corporation (NYSE:HEXO)(TSX:HEXO), Aphria Inc. (NYSE:APHA) (TSX:APHA), Tilray Inc. (NASDAQ:TLRY), and OrganiGram Holdings Inc. (TSX-V:OGI)(NASDAQ:OGI).
XPhyto Therapeutics Corp. (CSE:XPHY) BREAKING NEWS: XPhyto Therapeutics Corp. just announced it has closed both the definitive share purchase agreement with Vektor Pharma TF GmbH and the equipment purchase agreement entered into with an affiliated company of Vektor, both of which were previously announced by the Company on August 26, 2019. Vektor is a German narcotics manufacturer, importer, and researcher located approximately 170 kilometers west of Munich. For over a decade, the company and its team have been leaders in the design, testing and manufacture of thin film drug delivery systems, particularly transdermal patches and sub-lingual (oral) strips for the clinical management of pain. Vektor holds a number of valid narcotics licences pursuant to EU GMP certification and other governing regulations: Import Permit for drug dosage forms; Import Permit for cannabis; Manufacturing Permit for clinical samples; Manufacturing Permit for final drug product release; Analytical Permit for chemical and physical testing; Permit to handle narcotic drugs; and a Permit to handle animal tissue. Vektor’s various narcotics licences include authorizations related to conventional and cannabis-related prescription medications, including but not limited to: Buprenorphine, cannabis, Dronabinol, Fentanyl, Hydromorphone, Oxycodone, and THC. “The Vektor transaction will accelerate XPhyto’s medicinal cannabis import into Germany and its drug delivery expertise, both of which are a critical part of our near-term revenue generation strategy,” said Hugh Rogers, CEO of XPhyto. “Further, with vape-based delivery systems now associated with significant potential health risks, XPhyto is extremely pleased to combine assets and expertise with Vektor, a specialist in thin film drug delivery systems. XPhyto is well positioned to capitalize on the next generation of cannabis investment opportunities, primarily clinical validation of safe and effective medicine and emerging European markets.”
Other cannabis-related developments from around the markets include:
HEXO Corporation (NYSE:HEXO)(TSX:HEXO) just announced that its dried flower cannabis products are now available to Ontario consumers, after finalizing terms with the Ontario Cannabis Store (OCS). HEXO now adds nine of its dried flower offerings in both 3.5g and 15g SKUs to the OCS, including the Company’s award-winning Helios dried flower, which was named Best Sativa at the O’Cannabiz 2019 Industry Awards. “We are thrilled to increase our offering at the OCS,” said HEXO Corp CEO and co-founder, Sebastien St-Louis. “Apart from being our nation’s most populous province with the highest demand for cannabis products, the Ontario marketplace is among the most competitive—and we are rolling out high quality products to which we believe Ontario consumers will strongly gravitate.”
Aphria Inc. (NYSE:APHA)(TSX:APHA) just posted its results for the fourth quarter and fiscal year ended May 31, 2019. “It’s a new day at Aphria. Our team’s solid execution across key areas of our business resulted in strong adult-use revenue growth and a profitable fourth quarter,” stated Irwin D. Simon. “Over the last six months, our organization identified immediate priorities to help generate substantial progress near-term and long-term. We built upon existing business fundamentals and capabilities, streamlined processes, strengthened governance, and focused on building brand awareness. Together, we have nurtured an entrepreneurial culture of accountability through data-driven decision-making for value creation in the global medical and adult-use cannabis industry. Today’s Aphria has a stronger foundation for long-term growth and success.” The company posted net revenue of $128.6 million in the fourth quarter, an increase of 75% from prior quarter and 969% from prior year; revenue for adult-use cannabis of $18.5 million in the fourth quarter, up 158% from prior quarter; and net income of $15.8 million and adjusted EBITDA of $0.2 million in the fourth quarter.
Tilray Inc. (NASDAQ:TLRY) just announced it has entered into a definitive agreement pursuant to which Tilray, through a wholly-owned subsidiary of High Park Holdings Ltd., will acquire all of the issued and outstanding securities of 420 Investments Ltd., an adult-use cannabis retail operator headquartered in Calgary, Alberta. FOUR20 provides adult-use cannabis consumers with a premium retail experience focused on high quality product selection, education and community. FOUR20 currently operates six licensed retail locations and has 16 additional high traffic locations secured in desirable locations in Alberta, including Canmore, Calgaryand Edmonton. Tilray and High Park will leverage FOUR20’s retail expertise and brand and market knowledge to expand into other Canadian provincial markets where Licensed Producer retail ownership will be permitted in the future. “FOUR20 offers a premium retail experience for the mainstream cannabis consumer and builds on our broader retail strategy, which includes several minority investments in other leading cannabis retailers,” says Tilray Chief Corporate Development Officer Andrew Pucher. “With FOUR20, we will elevate the retail experience for consumers by offering the best quality-tested products while preparing for the next wave of legalized product launches taking place by year’s end.”
OrganiGram Holdings Inc. (TSX-V:OGI)(NASDAQ:OGI) just announced it entered into an advance payment and purchase agreement with 703454 N.B. Inc. (carrying on business as 1812 Hemp) under which the Company will pre-fund hemp purchases to receive access to as much as 60,000 kilograms of dried hemp flower to be harvested in calendar 2019 for extraction into cannabidiol isolate. Organigram is already a party to a purchase agreement entered into in January 2019 with 1812 Hemp, in which Organigram was granted a right of first refusal on 1812 Hemp’s production of certain hemp cultivars. Access to CBD-rich hemp flower is being facilitated through the Payment Agreement as the Company will advance funds to 1812 Hemp for their purchase of specialized large-scale hemp harvesting and processing equipment to maximize crop yields, contribute to increased efficiency and improve preservation of harvested cannabinoids. Purchase conditions for the dried hemp flower continue to be governed by the January Purchase Agreement which secures supply and supports research and development on the genetic improvement of hemp through traditional plant breeding methods.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated three thousand five hundred dollars for news coverage of the current press releases issued by XPhyto Therapeutics Corp. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
Tuesday, September 17th, 2019UncategorizedComments Off on $OGI Among Top Companies Disrupting a Massive $23.7 Billion Medical Cannabis Market
KELOWNA, BRITISH COLUMBIA / September 17, 2019 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that final study results of the 2018 human clinical study evaluating CBD delivery and effectiveness using its patented DehydraTECHTM powered TurboCBD™ capsules have been published in the peer reviewed medical journal, “Advances in Therapy”. Advances in Therapy focuses on clinical medicine and pharmaceutical research and has been published continually since 1984.
Key findings highlighted in the publication were as follows:
CBD in-plasma levels with the TurboCBD™ 90 mg dose were significantly higher than with the generic 90 mg dose at both 90 and 120 min (p < 0.05);
Only the TurboCBD™ 90 mg dose was elevated (i.e., greater than placebo) at 30 min (p < 0.05) and remained elevated (i.e., greater than placebo) at 4 h (p < 0.01);
Mean arterial blood pressure (MAP) in a subgroup analysis was significantly decreased with only the TurboCBD™ 90 mg dose relative to baseline (p < 0.05); and
Cerebral perfusion analysed by an index of conductance in the middle cerebral artery (MCA) in this subgroup was significantly higher with only the TurboCBD™ 90 mg dose relative to baseline (p < 0.001).
The study was conducted and well tolerated in 12 healthy young male athletes and the investigators concluded that further studies are warranted, noting in particular that “further acute and chronic dosing investigations in older and cerebrovascular-compromised patients may shed light on the vascular and clinical impacts of increased CBD bioavailability.”
Lexaria’s recent receipt of two granted patents for “treating certain conditions including, but not limited to heart disease, neurological diseases such as Alzheimer’s, Parkinson’s, schizophrenia” and others is timely considering the demonstrated effectiveness of DehydraTECH technology in increasing cerebral blood flow, and thus perhaps an increased effectiveness at delivering certain drugs to the brain.
Finally, it is worth noting that the publication also references a separate recent study published by other investigators who evaluated a comparable CBD dose with bioabsorption findings representative of the cannabinoid edibles industry sector in general. The differences in blood concentration between the TurboCBD 90 mg dose and the competitor’s 100 mg dose are shown in the graph above, where time to maximum plasma CBD concentration with the competitive formulation required ~4 hours whereas it was evidenced with the TurboCBD™ 90 mg dose within 90-120 min. The rate of bioabsorption of the CBD with the competitive 100 mg formulation was virtually nondetectable within 30 minutes of administration.
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH™ drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
Tuesday, September 17th, 2019UncategorizedComments Off on $LXRP Human CBD Study Results Published in Peer Reviewed Clinical Journal
Shea’s 30-Year Diverse Experience in Acquisitions, Capital Markets, SEC Reporting, and Leading Financial Organizations Bolsters PBI’s Strong Senior Management Team
South Easton, MA, Sept. 17, 2019 — via NEWMEDIAWIRE — Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that Mr. Daniel J. Shea has joined the Company as Sr. Vice President and Chief Financial Officer (“CFO”) effective Friday, September 13, 2019. In this key leadership position, Mr. Shea will be responsible for directing and overseeing all aspects of the Finance and Administration functions of the Company, including financial reporting and analysis; compliance with GAAP and applicable laws and rules for financial and tax reporting; forecasting and budgeting; primary liaison with the Company’s independent accounting firm; and leadership in the development of short and long-term financial objectives.
“It’s an exciting time to join Pressure BioSciences,” said Mr. Shea. “PBI’s unique platform technologies, worldwide customer base, growing revenue stream, and strong management team position the Company well to capitalize on substantial growth opportunities across the globe. I stand ready to support the Company’s commitment to high-quality financial reporting and internal control as it navigates through these opportunities in the coming years. I look forward to using my background and skills to facilitate the Company’s growth while we bring increased value to all shareholders.”
Mr. Shea, age 54, has over 30 years of experience in leading and advising financial organizations. Since January 2017, he has operated Woodcliff Advisors LLC, a CPA advisory firm providing counsel to boards, CFOs and senior management. Through Woodcliff, Mr. Shea personally filled CFO roles at public and private companies in the financial services and technology industries. From 1998 to 2016, he was a Senior Vice President at Affiliated Managers Group, Inc., a publicly traded asset management holding company with a long record of growth through acquisition. His core experience is in acquisitions, SEC reporting, internal controls, and the capital markets. Previously, he advised financial services firms at PricewaterhouseCoopers where his clients included asset managers, banks, private equity firms, mutual funds and leasing companies. Mr. Shea is a certified public accountant and earned his B.S. in Finance and Accounting from Boston College.
Mr. Richard T. Schumacher, President and CEO of PBI, added: “We are pleased to have someone with Dan’s experience and capabilities join PBI at such an important time in our corporate evolution. We believe all three of our patented technology business platforms have the potential for rapid growth over the next 12-18 months. To that end, we have given guidance that we believe total revenue in 2020 will be more than double total revenue of 2019. Such rapid growth will require reliable and supportive financial systems to be securely in place to facilitate smooth and timely financial reporting. It will also require a close and continued relationship with the capital markets. We are fortunate to have a seasoned financial professional like Dan join us at this most important time, to lead this financial transformation.”
Mr. Schumacher continued: “I will be transferring many responsibilities to Dan that have been on my plate as interim CFO. This welcomed transition will allow me to focus time on multiple opportunities that we believe offer great potential for commercial growth and increased financial security for PBI, including strategic partnerships, collaborations, acquisitions, and customer adoption/revenue acceleration programs. This is a very exciting time for stakeholders in PBI.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., CBD Oil and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
La Jolla, CA., Sept. 17, 2019 — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that RJ Tesi, M.D., Co-Founder and CEO, and Mark Lowdell, Ph.D., Co-Founder and Chief Scientific Officer, will present at the first ever Targeting Innate Immunity Congress, taking place in the biotech hub of Cambridge, Mass. from Sept. 23 through 25.
The conference is an opportunity for INmune Bio to showcase its two leading innate compounds in the hopes of improving the treatment of cancer to industry leaders, experts, academic researchers and clinicians in the field of innate immunity. In addition to presenting at the conference, Dr. Tesi and Dr. Lowdell will be instructing a course on the role of the tumor microenvironment (TME) in immunosuppression.
“This panel will bring together other experts from industry and academia to explore the role of the innate immune system in the TME and in cancer drug development,” said Dr. Tesi.
In addition to speaking at the Targeting Innate Immunity Congress this month, Dr. Tesi will also take part in a speaking engagement at the second annual MarketsandMarkets Next Gen Immuno-Oncology Congress on Sept. 19 in Philadelphia.
Below is a schedule of upcoming presentations:
MarketsandMarkets Next Gen Immuno-Oncology Congress Thursday, September 19 at 11:40 a.m. “Reversing Trastuzumab Resistance in HER2+ Breast Cancer”
Dr. Tesi will discuss Mucin 4 (MUC4) protein and how it predicts trastuzumab resistance in HER2+ breast cancer, the role of soluble tumor necrosis factor (TNF) in MUC4 expression and how INmune Bio’s drug candidate, INB03 works in combination with trastuzumab to reverse resistance in MUC4/HER+ breast cancer.
Targeting Innate Immunity Congress Monday, September 24 at 3:30 – 6:00 p.m. Short Course: “Understanding and Modulating Tumor Microenvironment for Immunotherapy”
Dr. Tesi and Dr. Lowdell will instruct an interactive short course on the role of the tumor microenvironment (TME) in immunosuppression. They will discuss strategies to change the immunosuppressive nature of the TME to one that supports immune responses and enhances the impact of tumor immunotherapy. Those who attend will walk away with an understanding of the following:
Role of the TME in immunosuppression
Checkpoint inhibitor optimization
Targeting of regulatory cells
Reprogramming of immunosuppressive cells
Modulation of chemokines and cytokines in the TME
Modification of tumor-reactive lymphocytes to evade the TME
Wednesday, September 25 at 11:40 a.m. “Myeloid Derived Suppressor Cell (MDSC): The Queen Bee of the Tumor Microenvironment (TME)”
As part of the “Modulating Macrophages in the Tumor Microenvironment” panel, Dr. Tesi will discuss targeting myeloid derived suppressor cells (MDSCs) as an efficient way to reverse tumor microenvironment (TME) immunobiology. His discussion will address the complexity of TME and how it contributes to failure of therapy, as well as understanding how targeting soluble tumor necrosis factor (TNF) offers a solution to the resistance to therapy when part of combination therapy. Dr. Tesi will also discuss the results of the Phase I trial for INmune Bio’s drug candidate, INB03 in patients with advanced cancer.
Wednesday, September 25 at 1:45 p.m. “What do Tumor Cells do to NK Cells? – Harnessing the Tumor-NK Interaction for Clinical Benefit”
Dr. Lowdell will participate in the “Advancing Innate Cell Therapies to the Clinic” portion of the conference to discuss how relapsed cancer cells evade natural killer (NK) cells, and how priming NK cells could effectively kill these cancer cells. Dr. Lowdell will also discuss INmune Bio’s INKmune™ drug candidate.
About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid-derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INBO3 and XPro1595 is still in clinical trials and has not been approved and there cannot be any assurance that it will be approved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO
(858) 964-3720
DMoss@INmuneBio.com
Toronto, Ontario–(September 16, 2019) – Capital 10X announces the release of an Initiation Report on the Organic Cannabis Market that features The Green Organic Dutchman among other organic cannabis producers.
The global market for organic products is currently worth $160 billion and is forecast to grow to $323 billion by 2024, a 15% annual growth rate. Organic sales have been strong for decades growing at 12% a year since 2000.
In the near term, the Canadian cannabis market will be worth $5 billion and organic demand will ultimately make up 20% of the market, creating a $1 billion revenue opportunity. This would equal the medium-term demand potential of $8.5 billion for organic cannabis.
By 2020 there will only be four certified organic producers operating globally and their supply will struggle to keep up with rapidly growing demand.
We’ve assessed the top players, including The Green Organic Dutchman, Rubicon Organics, and 48 North to determine which stocks are best positioned to capitalize on this growing vertical.
SRAX has developed an exclusive consumer-managed data marketplace
The company offers its proprietary BIGtoken platform
SRAX has entered into new partnerships to launch BIGtoken’s BIG Rewards(TM)
SRAX Inc. (NASDAQ: SRAX) is a digital-marketing and data management technology company based in Los Angeles, California. The company provides marketers, content owners and consumers with tools to unlock the value of data. Its technology unlocks this data to reveal brands’ core consumers and their characteristics across marketing channels, enabling businesses to better reach their customer bases. Additionally, through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where consumers can own their own data and get paid for the release of that data. Via BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased.
Fundamentally, SRAX is focusing on privacy and data ownership – an invaluable approach in this age of Facebook, Twitter, Snapchat, LinkedIn and the like – along with concerns over the protection of personal data. The company’s vision is to build the most valuable opted-in consumer dataset worldwide. Today’s contemporary consumers expect to keep data private but also receive compensation for releasing data once they decide to do so. This critical need has created a…
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), an innovative biotechnology company, has set its sights on using its proprietary drug delivery technology to provide an alternative method of nicotine ingestion that is safer than smoking. An article further discussing the company reads, “The technology, known as DehydraTECH(TM), is a patented, cost-effective delivery mechanism that has been shown to improve the ingestibility of cannabinoids, vitamins, nonsteroid anti-inflammatory drugs (NSAIDs) and nicotine. Now, Lexaria has partnered with one of the world’s largest tobacco firms to develop new, reduced-risk, oral nicotine products using the technology (http://nnw.fm/8brW8). . . . The deal funds Lexaria’s R&D program — and consumer product development — in exchange for certain DehydraTECH license rights and a minority equity interest in Lexaria Nicotine, a wholly owned subsidiary of Lexaria Bioscience Corp. An initial tranche of $1 million has been provided, with additional phases providing up to $12 million total. Lexaria has granted a license for its technology to be used in nicotine-based, oral-format products on an exclusive basis in the United States and a nonexclusive basis elsewhere globally, for which it will receive royalties on every dollar of revenue generated utilizing its technology.”
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in more than 40 countries around the world and has patents granted in the United States and in Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
An audit done by a marijuana business association has revealed that the number of black market cannabis industry players is thrice the number of the licensed marijuana businesses in the state.
The audit, whose findings were made public on Wednesday, indicates that there are 2,835 illegal marijuana businesses operating within California while the statistics from the Bureau of Cannabis Control show that only 873 companies are licensed to conduct marijuana-related business activities within the state.
This means that the number of illicit players dwarfs those who are within the licensed marijuana space. The audit was done by an industry group called the United Cannabis Business Association.
Their findings are the latest indicator of how rocky the marijuana industry in California is, even at a time when the state promised that it was going to crack the whip on the black market starting in 2018.
Earlier this year, a financial audit backed by industry players estimated that approximately $8.7 billion was lost to unlicensed cannabis products in the state while licensed businesses sold marijuana products worth only $3.1 billion.
Such information has led players in the legal marijuana industry to put their elected leaders, law enforcement and industry regulators on the spot for failing to curb the illicit trade of marijuana within the state.
This frustration with the slow progress in dealing with the marijuana black market has even prompted some licensed marijuana businesses in Los Angeles to recommend that tougher measures, such as prosecuting offenders in federal courts and incarcerating them thousands of miles away from their homes, could be tried to send a strong message that illegal commercial marijuana activities wouldn’t be tolerated or handled with kid gloves.
However, California’s marijuana industry isn’t faced with only the black market as a stumbling block. The industry is also grappling with the bans imposed on marijuana business operations by most of the local authorities.
The bans have put the state and the local authorities on a collision course since the state says that marijuana deliveries can be made anywhere within the state while the local authorities insist that the law allows them to either accept or ban marijuana companies from operating within their jurisdictions.
This conflict may also be fueling the marijuana black market since there are people who would wish to access marijuana in those areas where cannabis businesses aren’t allowed to operate, and where there is a need, supply will always show up one way or the other.
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
Feedback from retailers confirms premium organic segment highly in demand
Price premium not a barrier for cannabis consumers looking for high-quality
TGOD’s high-THC strain, Unite Organic, performing well in premium segment with positive consumer feedback
Company already received second order from the OCS as some retailers quickly sold out
TORONTO, Sept. 12, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF), a leading producer of premium certified organic cannabis, is pleased to announce that following its launch in Ontario at the end of August, which marked the Company’s entrance into Canada’s recreational market, initial demand has exceeded expectations. TGOD’s high-THC signature strain, Unite Organic, is performing well online and at dispensaries, triggering a second order from the OCS earlier than initially anticipated.
“We are thrilled to witness such strong sales and positive feedback from retailers and consumers across Ontario, Canada’s most populous province at 14.32 million people. We can see from the initial response that demand for high-quality flower is strong,” commented Brian Athaide, CEO of TGOD. “Our team is working hard to ramp up production of our premium organic products as we get ready to expand distribution with additional strains and product forms as well as to other provinces in the months ahead. With our Hamilton hybrid greenhouse completed, and a second one nearing completion in Valleyfield, we are on track to distribute nationally early next year.”
As highlighted in a study conducted by Hill & Knowlton earlier this year, over 50% of recreational consumers who intended to purchase cannabis stated that it is important that their cannabis be organic. TGOD’s cannabis is grown in the Company’s proprietary living soil, in accordance with all-natural principles and without irradiation. The Company’s growing process is also certified organic by both Pro-cert and ECOCERT, two leading organic certification bodies, providing consumers with a safe, consistent, and enjoyable cannabis experience.
About The Green Organic Dutchman Holdings Ltd. The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.
TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.
For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.
Forward-Looking Information Cautionary Statement
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about the availability of the Company’s products at the Ontario Cannabis Store or other retailers, plans to offer certain products to various provinces, statements about future production capacity, statements about the receipt of any regulatory permits or licences, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.
Thursday, September 12th, 2019UncategorizedComments Off on $TGODF $TGOD Strong Demand for Premium Organic Cannabis Following Ontario Launch
The CBD story is exploding. At current pace, The Brightfield Group says CBD sales could explode to $23.7 billion by 2023. In fact, “The bulk of this growth is coming from large retailers like CVS, Walgreens, and Kroger entering the market and providing that availability to consumers,” says Brightfield Managing Director, Bethany Gomez. Already, major retailers are just beginning to embrace CBD thanks to sizable consumer demand. To date, Neiman Marcus, Sephora, Vitamin Shoppe, Kroger, Barney’s DSW, CVS, American Eagle, and Walgreen’s have all jumped at the opportunity. Even better, support for cannabis legalization is exploding. A Gallup survey found that 66% of Americans are in favor of legalization. That’s up from just 60% in 2016. That’s opening a wide range of opportunity for companies including The Yield Growth Corp. (CSE:BOSS) (OTC:BOSQF), Canopy Growth Corporation (TO:WEED) (NYSE:CGC), Green Growth Brands Inc. (CSE:GGB) (OTC:GGBXF), Charlotte’s Web Holdings Inc. (CN:CWEB)(OTC:CWBHF), and OrganiGram Holdings Inc. (TSX:OGI)(NASDAQ:OGI).The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. just announced it has entered into an agreement with Peak Performance Products Inc., who will act as the wholesale distributor for Yield’s Urban Juve hemp products within the health retail channel across Canada. Peak Performance has more than 20 years’ experience representing global health and wellness brands in the Canadian marketplace. They provide the highest quality natural health products to reputable retailers across Canada, with access to a network of more than 3,500 brick-and-mortar and online retailers, in multiple channels, nationwide. The agreement grants Peak Performance rights to distribute and sell Urban Juve products at wholesale to health retailers across Canada. Peak Performance will actively promote the sale and distribution of the Urban Juve product line across Canada. They will maintain a complete line of products on hand to ensure prompt service of all retailers. The agreement was signed September 9, 2019 and has a two-year term.In addition to ongoing marketing efforts, Peak Performance also will feature Urban Juve products at their booth at the Canadian Health Food Association trade show in Toronto on September 14th and 15th. This event is Canada’s largest trade show dedicated to natural health, specialty and organic products, and the Peak Performance booth will showcase Urban Juve samples, demonstrations and product knowledge to local and international attendees. “Peak Performance is a top distributor in Canada and has successfully worked with the health and wellness industry for more than 20 years,” says Sandi Lesueur, President of Urban Juve. “They’ve chosen to distribute Urban Juve products because of their uniqueness: our Ayurveda-inspired, hemp-infused products are unlike anything on the market. Our booth is always the busiest when participating at trade-shows. I expect the same at this weekend’s CHFA event.”
Other cannabis-related developments from around the markets include:
Canopy Growth Corporation (TO:WEED)(NYSE:CGC) just announced that it has received a license from Health Canada for its KeyLeaf Life Sciences facility in Saskatoon, Saskatchewan. Including the Smiths Falls site and the recently licensed BC Tweed extraction site, Canopy Growth now operates three significant extraction assets to support the throughput required for large scale value-add product development. Canopy Growth recently retrofitted the now fully licensed KeyLeaf facility in Saskatchewan, a company with over 50 years of experience in the extraction industry. This facility is expected to be online in the Fall of 2019 and has the capacity to extract up to 5,000 kilograms of hemp or cannabis biomass per day. The application for the license was submitted under KeyLeaf’s previous name, POS Management Corp. and will be updated in due course. The newly licensed extraction platform is located in close proximity to Canopy Growth’s large-scale outdoor hemp and cannabis grow operations. The Company looks forward to the additional capacity increasing production efficiency, augmenting output volume, and ultimately reducing operational costs for value-add products set to be rolled out in the Canadian recreational and medical markets at the end of calendar year 2019. “With this milestone, we are executing against the vision of making strategic investments today in order to deliver results over the long term,” said Mark Zekulin, CEO, Canopy Growth. “This license will ensure we have the supply of extraction inputs for the medical, CBD, and recreational markets, especially the next generation of value-add, high margin cannabis products here in Canada.”
Green Growth Brands Inc. (CSE:GGB)(OTC:GGBXF) just announced that it will open 100th Seventh Sense Botanical Therapy mall-based shop. The first Seventh Sense shop opened in early February. “This is a huge milestone for Green Growth Brands and Seventh Sense,” said Peter Horvath, CEO of Green Growth Brands. “We believe we have created the largest and most valuable network of brick and mortar CBD shops in the country.” Seventh Sense shops retail high-quality botanical therapy CBD-infused personal care and beauty products at affordable prices. The product offering includes over 100 SKUs across bath, body, face, therapeutic, and sleep categories.
Charlotte’s Web Holdings Inc. (CN:CWEB)(OTC:CWBHF) just announced that Russell Hammer has joined the Company as Chief Financial Officer, effective tomorrow, August 15, 2019. Mr. Hammer, who has most recently served as an advisor in private equity investments, brings more than 30 years of finance experience in the retail, tourism and technology sectors. With his experience leading multi-billion-dollar multinational companies, he is the latest top-tier executive to join Charlotte’s Web as the Company accelerates its growth and evolution into a global consumer packaged goods (“CPG”) brand. Mr. Hammer replaces Rich Mohr, who as CFO has overseen the Company’s successful transition to a publicly traded company and market leader in hemp CBD products. “Russ’s appointment aligns perfectly to support the Company’s evolution over the past few years from an early stage organization to a leading public company, into its next phase transitioning to a global CPG company. His breadth of international finance experience across a range of industries, as well as expertise in building operational infrastructure, applying forward-looking analytics, M&A, and accessing capital markets will help us scale the business in a financially stable way,” said Deanie Elsner, CEO of Charlotte’s Web.
OrganiGram Holdings Inc. (TSXV:OGI)(NASDAQ:OGI) just announced it entered into an advance payment and purchase agreement with 703454 N.B. Inc. (carrying on business as 1812 Hemp) under which the Company will pre-fund hemp purchases to receive access to as much as 60,000 kilograms of dried hemp flower to be harvested in calendar 2019 for extraction into cannabidiol isolate. Organigram is already a party to a purchase agreement entered into in January 2019 with 1812 Hemp, in which Organigram was granted a right of first refusal on 1812 Hemp’s production of certain hemp cultivars. Access to CBD-rich hemp flower is being facilitated through the Payment Agreement as the Company will advance funds to 1812 Hemp for their purchase of specialized large-scale hemp harvesting and processing equipment to maximize crop yields, contribute to increased efficiency and improve preservation of harvested cannabinoids. Purchase conditions for the dried hemp flower continue to be governed by the January Purchase Agreement which secures supply and supports research and development on the genetic improvement of hemp through traditional plant breeding methods.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid four thousand five hundred dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.
The former head of the FDA has said that the conflict between the federal and state marijuana laws has created regulatory gaps which have given chance to tainted or substandard products to enter the market, resulting in the fatal lung injuries that have been reported recently. He hinted that federal action could put an end to this problem.
In a series of tweets, Scott Gottlieb said that the permissive marijuana laws of different U.S. states cause him a lot of worry since they give adults unfettered access to recreational marijuana and yet there are no federal regulations to oversee the production and manufacture of those marijuana products.
In tweets over the weekend, Dr. Gottlieb admitted that illicit vape cartridges, including those that may contain CBD and THC, seem to be behind the spate of lung problems that have so far killed five people and injured hundreds more across the country.
Experts are of the view that those vape cartridges may have contained ingredients not sanctioned for use in vape products (vitamin E acetate, for example) and those ingredients become deadly when they are inhaled.
In a TV appearance, the former FDA commissioner said that states legalize recreational marijuana when they don’t have the capacity to regulate the industry properly, while the federal government which has this needed capacity remains aloof since marijuana is a controlled substance. And when problems arise, states blame the federal government for those problems.
Gottlieb hinted that there is a need for the federal government to rethink its position on marijuana so that it can be possible for legitimate entities that wish to conduct research on the substance to do so.
Without saying marijuana should be federally legalized, Gottlieb’s statement about the need for federal oversight suggests as much because the FDA can only oversee an industry that is legal under federal law.
He also said that under the current legal regime, the FDA may be unable to regulate any vape pens that aren’t intended to be used by the tobacco industry. Making the necessary change would require congressional action, he added.
It appears as though the country is at the same point that it was decades ago just before the prohibition of alcohol ended. At that time, people died after consuming tainted alcohol sold on the black market, and a decision was made to legalize alcohol so that the industry could be legalized. Could the injuries and fatalities attributed to illegal vape cartridges be likely to result in the federal legalization of marijuana?
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its receipt of United States Patent and Trademark Office (“USPTO”) formal notice of allowance to Patent Application Serial No. 15/776,061. The patent, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NUCROSIS FACTOR,” covers INmune’s INB03 Program that utilizes dominant negative TNFα (“DN-TNFα”) technology for treating cancer. “This is an important patent for INmune Bio, Inc. and provides exclusivity for use of our DN-TNFα technology for the treatment of cancer,” INmune Bio Assoc. General Counsel Joshua Schoonover said in the news release. “With the approval from the USPTO, and the positive indication of allowable subject matter in the international preliminary report on patentability for the corresponding international PCT patent application, published as WO/2017/106278, we expect this patent family should develop into global intellectual property rights.”
INmune Bio, Inc. is a clinical-stage immunology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing two product platforms, the DN-TNFα Platform and an Immune Priming Platform, as well as multiple products related to these platforms that reengineer the patient’s innate immune system’s response to disease. In addition to INB03, the DN-TNFα Platform includes XPRO1595, a DN-TNFα protein biologic that targets soluble TNFα (sTNFα) and may have many beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation; and NeuLiv, also a DN-TNFα protein biologic that may enable targeting of the underlying cause of non-alcoholic steatohepatitis (NASH), to help stop the disease and allow the liver to heal. The Immune Priming Platform includes INKmune, which is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and neurodegenerative diseases. For more information, visit the company’s website at www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://nnw.fm/INMB
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
TORONTO, Sept. 11, 2019 – Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, is pleased to announce the formation of its Strategic Advisory Board, a group of respected business leaders that will provide guidance to Canopy Rivers’ executive team as it continues to build and strengthen the Company’s global portfolio of leading cannabis companies.
“We have assembled a group of outstanding individuals with exceptional track records as leaders in their respective industries,” said Narbe Alexandrian, President and CEO of Canopy Rivers. “The Strategic Advisory Board will play an important role in providing guidance and insight to Canopy Rivers as we pursue our global growth strategy. Together, we look forward to building the cannabis industry of tomorrow, today.”
Inaugural members of Canopy Rivers’ Strategic Advisory Board include:
John Ruffolo – Mr. Ruffolo is the Co-founder and Vice Chair of the Council of Canadian Innovators. Mr. Ruffolo founded OMERS Ventures and also formed Platform Investments, OMERS’ innovation arm, where he led investments in Purpose Financial, PointNorth Capital, District Ventures, OneEleven and ArcTern Ventures. He sits on several boards, including Ether Capital, Ontario Centres of Excellence, and the Royal Ontario Museum.
Meg Lovell – Ms. Lovell served as Co-Head of M&A and as Corporate and Commercial Counsel at Imperial Brands PLC, a global consumer goods company with a portfolio of next-generation and tobacco products. During her time at Imperial Brands, Ms. Lovell led a number of strategic transactions with a particular focus on Imperial Brands’ next-generation product portfolio, in addition to advising on an extensive range of matters across the organization. Prior to joining Imperial Brands, Ms. Lovell was an Associate at Slaughter and May, a leading multinational law firm.
Philip Donne – Mr. Donne is a board advisor for several companies including Greenhouse Juice, Longo’s, Nature’s Path Foods, and Valens. He is the former President of Campbell Canada, the former President and CEO of Kellogg Canada, and the former President of Cossette’s Toronto office and Co-President of the agency’s Montreal Office. An award-winning marketing strategist, Mr. Donne received the Gold Medal Award from the Association of Canadian Advertisers and a Golden Pencil Award for his contributions to the Canadian food industry.
Canopy Rivers would also like to announce that Daniel Pearlstein, EVP, Strategy, is no longer with the Company. The Company would like to thank Mr. Pearlstein for his contributions to the Company and wishes him well with his future endeavors.
About Canopy Rivers:
Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.
Forward-Looking Statements
This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the role of the Company’s Strategic Advisory Board; the Company’s future plans and global growth strategy; and expectations for other economic, business, and/or competitive factors.
Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; changes in the role of the Strategic Advisory Board or the Company’s plans and growth strategy; the ability of the Company and the Strategic Advisory Board to collaborate; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ annual information form dated July 15, 2019, filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Wednesday, September 11th, 2019UncategorizedComments Off on $CNPOF $RIV Launches Strategic Advisory Board
Palm Beach, FL –September 11, 2019 – Recent advances in marijuana technology have changed the industry. From cultivation to consumption, technology is improving the end product and using new farming techniques to produce better strains. A recent article on the cannabis industry’s evolution said: “The cannabis industry is on a tremendous upswing, with numbers expected to reach $31.4 billion by the year 2021 (this according to Grand View Research, a cannabis market research firm). One of the factors that is pushing the industry ever upwards is a surge in marijuana technology that’s helping produce better crops, ensure the highest safety standards, connect consumers and cannabis businesses, and provide a variety of new options for consumption.” Active companies in the industry making moves to ready that include: GreenStar Biosciences Corp. (CSE: GSTR), The Yield Growth Corp. (OTCQB: BOSQF) (CSE: BOSS), The Supreme Cannabis Company, Inc. (OTCQX: SPRWF) (TSX: FIRE), OrganiGram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), MedMen Enterprises Inc. (OTCQX: MMNFF) (CSE: MMEN).
They continued saying: “The world of cannabis technology is fast-paced and ever-changing… As with all the other fields in the agriculture industry, cannabis cultivation has benefitted from the evolution of marijuana technology over the years. Marijuana growers are constantly finding new ways to grow more robust crops in less space and with less labor required.”
GreenStar Biosciences Corp. (CSE:GSTR) BREAKING NEWS: GreenStar Biosciences, a growth-oriented technology and services company that provides real estate, financial, management and other support to licensed cannabis businesses in the United States, is pleased to announce that it has received positive results from an initial cultivation test involving the growth of approximately 2,500 plants using the proprietary patent-pending grow and cultivation technology of Progressive Herbs Inc. (“Progressive”). As previously announced, Capri PHGS LLC (“Capri”), a 50/50 joint venture between the Company and Progressive, holds the exclusive license to utilize Progressive’s proprietary cultivation technology. The Company also received results from independent laboratory testing on the three strains used in the initial cultivation test, which demonstrated total cannabinoid percentages between 22.85% to 32.54%, depending on the strain tested.
Seeds from three different proprietary (by agreement) strains were planted inside a 200-square-foot room at Cowlitz County Cannabis Cultivation Inc.’s warehouse facilities in Washington State. The results of this initial cultivation test appear to validate several efficiencies and advantages of the proprietary cultivation technology compared to traditional greenhouse operations:
High total cannabinoid levels:
Higher than normal total cannabinoid percentages of three strains tested (22.85%, 30.61% and 32.54% (compared to industry averages of between approximately 15-23% for similar strains).
No use of pesticides, herbicides or fungicides.
Free of heavy metals and contaminants.
Lower operational costs::
Room used for the initial cultivation test was readied for seed planting in two weeks, using “off-the-shelf” environmental control products.
Preliminary evidence that plants can be grown in a sub-optimal space with minimal, low-cost equipment.
Lower electricity costs (initial testing showed production of approximately 3 grams per watt used compared to industry average of 1-1.5 grams per watt).
Faster harvest time:
All plants were harvested in approximately 72 days, allowing for up to five harvest cycles per year (compared to an average of three to four per year for a traditional indoor grow operation).
Independent laboratory testing on random flower samples of the harvested plants was conducted by Praxis Laboratory (“Praxis”), an accredited Washington State testing facility. Read the results and this entire release at:https://www.financialnewsmedia.com/news-gstr/
Additional industry related developments from around the markets:
The Yield Growth Corp. (OTCQB: BOSQF) (CSE: BOSS) has licensed its patent-pending proprietary technology for extracting key chemical compounds from hemp to its wholly owned subsidiary Yield Botanicals to establish a CBD (cannabidiol) extraction business in the United States.
Yield Botanicals is well positioned to capitalize on substantial growth in the CBD market. Its licensed patent-pending technology shows early promise of significantly increasing the yield of valuable chemical compounds per kilogram of hemp root input during the extraction process, as tested by an independent lab. Yield Botanicals intends to use the same technology as part of the CBD extraction process to increase the yield of CBD from hemp. It also intends to conduct research and development using the technology to create a water-soluble CBD for beverages and to create a CBD nano-emulsion to enhance transdermal bioavailability of topical products. Yield Botanicals also intends to conduct further research regarding a non-toxic plant-based surfactant it has identified to enable creation of clean CBD products.
The Supreme Cannabis Company, Inc.’s (OTCQX: SPRWF) (TSX: FIRE) 7Acres has launched a proprietary strain: Jack Haze. As 7Acres’ first sativa-dominant strain, Jack Haze delivers high tetrahydrocannabinol content with a terpinolene forward profile. Jack Haze is one of the few cultivars available with this dominant cannabis terpene, delivering a complex aroma with notes of citrus, pine and warm spice. True to its scent, Jack Haze offers a crisp, zesty, evergreen flavour. In October, 2018, 7Acres went to market with four core stains that were selected for their strong sensory characteristics. As it develops new genetics in house, 7Acres continues to prioritize subjective quality.
“Jack Haze’s novel name pays homage to the well-known Jack Herer strain. This cultivar’s expression possesses a unique haze profile with a classic, sweet sativa smell and strong visual appeal,” commented John Fowler, chief advocacy officer and founder. “As we develop and introduce unique strains, we further differentiate 7Acres’ high-end flower offering and continue to achieve premium pricing across Canada.”
OrganiGram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has received Health Canada’s approval for the licensing of 17 additional cultivation rooms under the Cannabis Regulations. The new cultivation rooms represent approximately 15,000 kilograms/year of increased target production capacity. These are the first 17 rooms licensed within the company’s phase 4B expansion and now bring the company’s Moncton facility to annualized licensed capacity to a target of 76,000 kg.
MedMen Enterprises Inc. (OTCQX: MMNFF) (CSE: MMEN) announces expiration of HSR waiting period for proposed acquisition of Pharmacann. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to Medmen Enterprises Inc.’s proposed acquisition of PharmaCann LLC. The expiration of the waiting period under the HSR Act satisfies one condition needed to close the transaction, which is expected to be completed by the end of calendar year 2019, subject to customary closing conditions.
“Today marks a monumental day for the cannabis industry,” said Adam Bierman, Medmen co-founder and chief executive officer. “We hope this will pave the way for other companies in what has become a highly acquisitive and dynamic industry.”
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press release issued above by GreenStar Biosciences Corp. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Wednesday, September 11th, 2019UncategorizedComments Off on $OGI Cultivation Smart Farming Technology Producing Better Strains
Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (SRUTF Profile) is developing new technology to manufacture cannabis edibles and to accurately measure their active ingredients. Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (LXRP Profile) has created a bold new technology to make cannabis’ active ingredients more palatable and absorbable. BevCanna Enterprises Inc. (CSE: BEV) (OTC: BVNNF) is producing white-label products, giving other brands access to the market. HEXO Corp. (TSX: HEXO) (NYSE: HEXO) is meeting its regulatory needs by acquiring other licensed cannabis producers and processors. Valens GroWorks Corp. (TSX.V: VGW) (OTCQX: VGWCF) has created a large and growing…
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask our Editor
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.
Wednesday, September 11th, 2019UncategorizedComments Off on $LXRP Technological Innovation Pushes Bounds of Edible Cannabis Market
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that non-affiliated, independent researchers have reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, prevented tumor growth in triple-negative breast cancer (“TNBC”). Currently considered an incurable cancer, there are limited therapeutic options available for TNBC. “The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging,” Genprex Chairman and CEO Rodney Varner said in the news release. “We believe that the data reported in this Nature article by independent researchers supports our belief that TUSC2 may be effective to treat a variety of cancers, including some of the most deadly types of cancer.”
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BMO’s block offering of TGOD’s shares was fully subscribed
TGOD’s CEO commented on the mutual benefits presented by the Aurora transaction
Investment interest in TGOD has been heightened following completion of the transaction
In the wake of The Bank of Montreal’s (BMO) completion of a block trade of Aurora Cannabis (TSX: ACB) (NYSE: ACB) held shares of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), leadership is reportedly pleased to see that 28.8 million overhanging shares remaining from that transaction have been successfully placed, predominately with institutional asset managers.
Through a transaction with BMO, a block trade of 4.8 million shares was completed on Friday, September 6, at $2.96, clearing the remaining shares. Approximately 55-65 percent of the total block of shares was placed in the hands of institutional asset managers, with the balance being taken by…
NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://nnw.fm/TGODF
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NEW YORK, Sept. 10, 2019 — via NetworkWire – SRAX, Inc. (NASDAQ: SRAX), a digital marketing and consumer data management technology company, today announces it has selected the corporate communications expertise of NetworkNewsWire (“NNW”).
SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.
Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation. BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. To date, there are 15.9 million BIGtoken registered users worldwide.
NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility. As part of the Client-Partner relationship with SRAX, NNW will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the company.
“SRAX understands what consumers want and has created a platform fulfilling the universal desire to have control over one’s own data,” states Sherri Franklin, Director of Client Solutions for NNW. “As the company focuses on expanding its market reach, we will execute a corporate communications campaign that places its strategy and accomplishments in front of the investment community.”
About SRAX, Inc.
SRAX, Inc. (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through the BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data thereby offering everyone in the Internet ecosystem choice, transparency, and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury, and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information on SRAX, visit www.srax.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
TORONTO, Sept. 10, 2019 – Canopy Rivers Inc. (the “Company” or “Canopy Rivers“) (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, is pleased to share that its portfolio company Herbert Works Ltd. (“Herbert Works“) has received its research and development (R&D) licence from Health Canada to develop branded cannabis-infused beverages.
“This announcement represents a significant milestone for Herbert Works as the company continues to move quickly toward the development of exceptional and widely appealing THC-infused beverages,” said Narbe Alexandrian, President and CEO of Canopy Rivers. “It’s a timely achievement, as the next wave of cannabis legalization in Canada will unlock these new product offerings in a matter of months. We believe that Herbert Works is in a prime position to capitalize on the growth opportunities that ‘Cannabis 2.0′ presents for consumers that are eager to try cannabis in different formats.”
Herbert Works’ mission is to combine advanced technology with its knowledge and appreciation of the experience-enhancing properties of cannabis to create products specifically designed around consumers’ many lifestyle needs. Canopy Rivers currently holds 23% of the equity of Herbert Works on a fully diluted basis (excluding a control warrant). For more information regarding Canopy Rivers’ investment in Herbert Works, please refer to the Company’s annual information form dated July 15, 2019 (“AIF“) filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com.
About Canopy Rivers:
Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.
Forward-Looking Statements
This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: Herbert Works’ ability to develop exceptional, widely appealing THC-infused beverages; the expectation that the next wave of cannabis legalization will unlock new product offerings in a matter of months; management’s belief that Herbert is in a prime position to capitalize on the growth opportunities presented by ‘Cannabis 2.0’; and expectations for other economic, business, and/or competitive factors.
Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; changes in Herbert Works’ ability to develop THC-infused beverages; Herbert Works’ actual ability to capitalize on growth opportunities; changes in consumer preferences and demands and the product offerings available to consumers; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ AIF, filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Tuesday, September 10th, 2019UncategorizedComments Off on $CNPOF $RIV Awarded Cannabis-Infused Beverages R&D Licence from Health Canada
Two Prestigious Research Centers Report PBI’s PCT Platform Delivers Superior Results for Protein Biomarker Discovery Studies from Preserved Cancer Biopsy Tissue Samples
SOUTH EASTON, MA, Sept. 10, 2019 — via NEWMEDIAWIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries. The Company announced today the publication of two scientific journal articles, led by independent teams of scientists in China and Australia, reporting excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers and potentially for use in clinical diagnostics based upon these markers. The Chinese team from Westlake University (Hangzhou, China) purchased their first two PCT platforms in 2017 and subsequently purchased four additional PCT systems. The Australian Proteome of Human Cancer (“ProCan”) team bought their first PCT system in 2016 and have subsequently added five more PCT platforms.
FFPE preserved tissue samples are an invaluable resource for retrospective studies of disease progression and response to therapy, because the disease outcome associated with the tissue and patient’s treatment history are known. Effective studies on these sample sets can accelerate discoveries of new therapies, drugs, and preventive strategies. FFPE has been long-established as the most common technique worldwide for the preservation of tissues for later study. Archival repositories exist that contain a total of millions to a billion or more FFPE tissue samples. However, the analysis of FFPE samples has historically been problematic. FFPE preservation techniques were designed for permanence and stability – hence it is challenging to reverse this fixation and to liberate and extract the important biomolecules relevant as cancer biomarkers. Significantly, both publications cited here, together with other publications (See PBI Website), now report excellent results using the PCT sample preparation platform for comprehensive and reliable extraction and presentation of important proteins for analysis, from both FFPE and fresh frozen tissue samples.
Mr. Richard T. Schumacher, President and CEO of Pressure BioSciences, commented: “It is estimated (Nature volume 448, pages 959–962, 23 August 2007) that well over one billion archival FFPE tissue samples exist in pathology and other laboratories worldwide. We believe there are millions of new FFPE tissue samples processed and stored each year. These samples offer the promise of unveiling invaluable information that can lead to the development of new treatments, cures, and preventive measures for cancer and many other diseases. However, up to now, it has been very difficult to extract this information from biomolecules in FFPE samples.”
Ms. Roxana McCloskey, Director of Marketing and Sales at PBI, said: “We believe that our PCT platform is establishing itself as the method of choice for the superior extraction of potential biomarkers and their presentation for the effective proteomic analyses that will propel the growth of this huge market. We expect this exciting, now proven application of our PCT Platform for protein biomarker discovery in fresh frozen and FFPE biopsy samples to manifest itself in increased instrument sales starting in the second half of 2019.”
The global cancer biomarkers market alone is expected to exceed more than US $157 Billion by 2022 (MarketWatch – January 8, 2019).
In their publication High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification, Professor Tiannan Guo, Laboratory Director at Westlake University, explained: “We developed the PCT-SWATH/DIA method of coupling pressure cycling technology for sample preparation with a high throughput mass spectrometry workflow, to analyze FFPE tissue proteomes. We showed that our workflow is a robust and reproducible proteomic method to analyze FFPE tissues from both bulk tissue and tiny biopsy samples as well as sectioned tissue slices.”
Dr. Guo continued, “We believe that the vast reservoirs of historical FFPE tissue samples accumulated in biobanks worldwide offer enormous potential using our methods for biomarker discovery, by leveraging thepracticality and superiority of PBI’s PCT sample preparation platform for maximizing the diversity and abundance of results from FFPE samples (over even fresh frozen samples), followed by mass spectrometry analysis in the PCT-SWATH/DIA workflow.”
Professor Phil Robinson, Co-Director of ProCan, stated: “The key to clinical application of tissue-based proteomics is to adapt to the practical requirements of clinical workflow. Our results from FFPE tissues following PCT sample preparation are consistent with other reports showing that high quality data can be generated and that the scale and scope of quantifiable proteins is comparable to that obtained from fresh frozen tissues.”
Professor Robinson continued: “After samples are collected, tissue lysis and digestion protocols must be rapid, efficient, reproducible and broadly applicable to tissues of different kinds and from different source laboratories. In addition, the methodology should be adaptable for integration of robotics to facilitate high throughput where possible. ProCan has instituted the use of pressure cycling technology (PBI Barocyclers) to achieve consistent and superior lysis and digestion of tissue samples.” (Addressing the challenges of high-throughput cancer tissue proteomics for clinical application: ProCan®).
About Westlake Institute for Advanced Study (now Westlake University)
Westlake Institute for Advanced Study (“WIAS”) is a non-profit research institute dedicated to the advancement of natural sciences and the frontiers of engineering disciplines. Located in the beautiful Cloud Town of Xihu District, Hangzhou, China, WIAS strives to represent the scientific strength of China, to influence the nation’s future, and to promote inclusive development and progress. WIAS, now grown into Westlake University, aims at establishing a top-level research-oriented global university. At WIAS, scientific knowledge and technological advancement are utilized to have a real-life impact on the world and to benefit human beings. Leading talent with innovative spirit and capabilities are trained to become the driving force of China’s development.
About ProCan
The Australian Cancer Research Center Foundation International Centre for the Proteome of Cancer (“ProCan”) is located in newly renovated laboratory facilities at the Children’s Medical Research Institute (“CMRI”) near Sydney, Australia. The goal of ProCan is to analyze over 70,000 cancer samples from all over the world over the next 5 years, with over 10,000 samples completed to date. This will enable a better understanding of cancer, as well as provide a means of personalized precision diagnosis and treatment, giving clinicians the information needed to decide on the best option for each individual patient. CMRI is an official collaborator of the US National Cancer Institute’s Cancer Moonshot initiative, with a key objective to accelerate what would normally take ten years of cancer research to completion in five years.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., CBD Oil and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
For regular updates, connect with Lexaria on Twitter (
and on Facebook